Literature DB >> 19508941

Treatment and outcomes of large vessel arteritis.

Frances A Borg1, Bhaskar Dasgupta.   

Abstract

Giant cell arteritis (GCA) and Takayasu's arteritis (TA) are characterised by systemic inflammation and critical ischaemia. GCA is a medical emergency. Neuro-ophthalmic complications occur early, with permanent vision loss in up to a fifth of patients, resulting mainly from failure of prompt recognition and treatment. Diagnosis of large vessel vasculitis is often delayed due to poor recognition of early, often non-specific symptoms. Laboratory inflammatory markers are often discordant with disease activity. Modern imaging techniques show promise in diagnosis and disease monitoring, improving our understanding of major artery involvement in large vessel vasculitis. However, in practice, their role is still unclear. The mainstay of therapy remains corticosteroids. Experience using conventional disease-modifying drugs is mixed, and biological therapies require further evaluation for their steroid-sparing potential.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19508941     DOI: 10.1016/j.berh.2009.04.001

Source DB:  PubMed          Journal:  Best Pract Res Clin Rheumatol        ISSN: 1521-6942            Impact factor:   4.098


  9 in total

1.  Development of outcome measures for large-vessel vasculitis for use in clinical trials: opportunities, challenges, and research agenda.

Authors:  Haner Direskeneli; Sibel Z Aydin; Tanaz A Kermani; Eric L Matteson; Maarten Boers; Karen Herlyn; Raashid A Luqmani; Tuhina Neogi; Philip Seo; Ravi Suppiah; Gunnar Tomasson; Peter A Merkel
Journal:  J Rheumatol       Date:  2011-07       Impact factor: 4.666

2.  Role of 18F-fluorodeoxyglucose positron emission tomography/computed tomography for therapy evaluation of patients with large-vessel vasculitis.

Authors:  Francesco Bertagna; Giovanni Bosio; Federico Caobelli; Federica Motta; Giorgio Biasiotto; Raffaele Giubbini
Journal:  Jpn J Radiol       Date:  2010-05-01       Impact factor: 2.374

3.  Serum amyloid A is a useful marker to evaluate the disease activity of Takayasu's arteritis.

Authors:  Tomohiro Koga; Yuichiro Nishino; Junya Makiyama; Takeshi Hayashida; Taichiro Miyashita; Yasumori Izumi; Mami Tamai; Atsushi Kawakami; Katsumi Eguchi; Kiysohi Migita
Journal:  Rheumatol Int       Date:  2009-12-18       Impact factor: 2.631

4.  Vascular surgery: the main risk factor for mortality in 146 Takayasu arteritis patients.

Authors:  Nilton Salles Rosa Neto; Samuel Katsuyuki Shinjo; Maurício Levy-Neto; Rosa Maria Rodrigues Pereira
Journal:  Rheumatol Int       Date:  2017-02-21       Impact factor: 2.631

Review 5.  Assessment of disease activity and progression in Takayasu's arteritis.

Authors:  Haner Direskeneli; Sibel Z Aydin; Peter A Merkel
Journal:  Clin Exp Rheumatol       Date:  2011-05-11       Impact factor: 4.473

6.  Dyspnea due to pulmonary vessel arteritis.

Authors:  Suzana M Gilmour; Giulio Stuart Dominelli; Jonathon A Leipsic; Robert D Levy
Journal:  Can Respir J       Date:  2014-02-12       Impact factor: 2.409

7.  Effect of CRP value on 18F-FDG PET vascular positivity in Takayasu arteritis: a systematic review and per-patient based meta-analysis.

Authors:  Léa Gomez; Philippe Chaumet-Riffaud; Nicolas Noel; Olivier Lambotte; Cécile Goujard; Emmanuel Durand; Florent L Besson
Journal:  Eur J Nucl Med Mol Imaging       Date:  2017-08-30       Impact factor: 9.236

Review 8.  Non-invasive imaging of vascular inflammation.

Authors:  Enrico Ammirati; Francesco Moroni; Patrizia Pedrotti; Isabella Scotti; Marco Magnoni; Enrica P Bozzolo; Ornella E Rimoldi; Paolo G Camici
Journal:  Front Immunol       Date:  2014-08-18       Impact factor: 7.561

9.  Effects of glucocorticoids and tumor necrosis factor-alpha inhibitors on both clinical and molecular parameters in patients with Takayasu arteritis.

Authors:  Raffaele Serra; Raffaele Grande; Gianluca Buffone; Edoardo Scarcello; Fabio Tripodi; Pierandrea Rende; Luca Gallelli; Stefano de Franciscis
Journal:  J Pharmacol Pharmacother       Date:  2014-07
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.